Glioblastoma, notorious for its invasiveness and poor prognosis, has long posed a formidable challenge to oncologists and neuroscientists alike. The conventional strategies involving surgical excision, radiation, and chemotherapy offer limited long-term success, with a grim five-year survival rate lingering around 15 percent. Despite aggressive treatment, glioblastoma cells frequently infiltrate healthy brain tissue, enabling rapid tumor regrowth. The failure of existing drugs to effectively penetrate tumor masses and the resilience of cancer cells underscore the urgent need for innovative therapeutic approaches that address not only the cells but also their immediate environment.

Central to the Cambridge study is hyaluronic acid (HA), a naturally occurring polysaccharide abundant in the brain’s extracellular matrix. HA forms a critical scaffold that provides structural support and modulates cellular behavior. The research team revealed that the intrinsic molecular flexibility of HA molecules is essential for glioblastoma cell invasion. This flexibility allows HA to adopt conformations that bind to CD44, a receptor expressed on the surface of cancer cells, which in turn triggers signaling pathways promoting motility and invasion. The dynamic interplay between HA and CD44 orchestrates the malignant spread characteristic of glioblastoma.

Employing advanced nuclear magnetic resonance (NMR) spectroscopy, the researchers meticulously analyzed the conformational states of HA molecules. They discovered that when HA’s molecular flexibility is chemically restricted—achieved through cross-linking that ‘freezes’ its shape—the ability of HA to engage CD44 is dramatically diminished. This inhibition effectively reprograms glioblastoma cells into a dormant, non-invasive state without inducing cell death. Unlike traditional cytotoxic therapies, this approach leverages changes in the tumor microenvironment to modulate cellular behavior, offering potential for therapies with fewer side effects and reduced resistance.

The implications of this finding are profound. By stabilizing HA, the extracellular matrix transitions from a permissive to a restrictive environment, curtailing the spread of cancer cells throughout brain tissue. This strategy directly addresses one of the key challenges in glioblastoma treatment: the diffuse infiltration of tumor cells into healthy brain regions that are beyond the reach of surgical removal or systemic chemotherapy. By arresting invasion at the molecular level, this matrix-based therapy may substantially delay or even prevent tumor recurrence.

Importantly, the research indicates that these effects occur at relatively low concentrations of HA, suggesting that physical entrapment of cancer cells is not the primary mechanism. Instead, the biochemical signaling cascade between HA and CD44 is disrupted, leading to alterations in cell motility and gene expression that favor dormancy. This nuanced understanding of tumor biology underscores the complexity of the tumor microenvironment and highlights how physical and biochemical factors integrate to regulate malignancy.

The study also sheds light on the perplexing phenomenon of glioblastoma recurrence at surgical sites. Postoperative edema—the accumulation of fluid—can dilute and increase the flexibility of HA, inadvertently restoring the molecule’s ability to bind CD44 and promote invasion. By applying HA-stabilizing agents at or near surgical sites, it may be possible to mitigate this risk, offering a means to extend remission times and improve patient outcomes.

This innovative approach opens the door not only for glioblastoma but also for a broader range of solid tumors where the extracellular matrix plays a pivotal role in cancer progression. Many invasive cancers exploit their microenvironment to escape immune surveillance and therapeutic agents. By focusing on altering the mechanical and chemical properties of the matrix, new classes of anti-invasive therapies could emerge, potentially applicable across oncology.

Professor Melinda Duer, who spearheaded this research at the Yusuf Hamied Department of Chemistry at the University of Cambridge, emphasized the groundbreaking nature of this work: “Our results provide the first compelling evidence that reprogramming cancer cells by targeting the matrix rather than the cells themselves is feasible. We have demonstrated that cancer cell behavior can be fundamentally altered by controlling the flexibility of hyaluronic acid, halting their invasive capability without toxicity.” This paradigm shift in cancer treatment underscores the significance of the microenvironment in oncogenesis.

Further studies are planned to validate these findings in animal models, an essential step before contemplating clinical trials in humans. The potential translation of HA ‘freezing’ techniques into viable therapeutics hinges on demonstrating efficacy and safety in vivo. The team’s multidisciplinary approach, combining chemistry, biology, and oncology, exemplifies the innovative strategies necessary to tackle complex malignancies like glioblastoma.

The research was supported by prestigious funding bodies including the European Research Council and the UK’s Engineering and Physical Sciences Research Council, underscoring its significance and the high level of scientific rigor involved. As this work advances, it promises to inspire a new wave of matrix-based cancer therapies that could revolutionize treatment paradigms and offer hope to patients afflicted by this devastating disease.

Scientists around the world eagerly await further developments from the University of Cambridge team’s pioneering work. Should ongoing studies confirm these promising initial results, the clinical landscape for glioblastoma—and possibly other invasive cancers—may witness a transformative shift, leveraging the structural properties of the extracellular matrix to achieve therapeutic breakthroughs where traditional methods have failed.

Subject of Research:
Article Title: Molecular flexibility of hyaluronic acid has a profound effect on invasion of cancer cells
News Publication Date: 27-Aug-2025
Web References: http://dx.doi.org/10.1098/rsos.251036
References: Royal Society Open Science
Keywords: Cancer; Brain cancer; Glioblastomas; Glioblastoma cells; Cancer cells; Health and medicine

Central to the fibrosis-to-cancer axis are hepatic stellate cells (HSCs), resident pericytes of the liver that, upon activation by chronic insults such as viral hepatitis or excessive alcohol consumption, transdifferentiate into myofibroblast-like cells. Activated HSCs are primarily responsible for the excessive deposition of extracellular matrix (ECM) components, forming the dense scar tissue characteristic of fibrosis. However, their role extends far beyond simple scar production. These cells secrete a broad range of bioactive molecules, including vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1), which enhance tumor angiogenesis and fuel the growth of neoplastic cells.

Importantly, activated HSCs contribute to immune modulation within the tumor microenvironment. Through the expression of immune checkpoint molecules such as programmed death-ligand 1 (PD-L1), they suppress immune surveillance mechanisms that would otherwise recognize and eliminate emerging cancer cells. This immunosuppressive milieu effectively cloaks pre-malignant and malignant cells from cytotoxic T lymphocytes, facilitating unchecked tumor progression. Additionally, HSCs undergo phenotypic transformation into cancer-associated fibroblasts (CAFs), a heterogeneous population that further modifies the ECM and secretes mitogenic and pro-inflammatory factors, thereby accelerating hepatocellular carcinoma malignancy.

At the molecular level, dysregulation of multiple signaling pathways orchestrates the fibrogenic and oncogenic programs in the liver. The TGF-β-Smad pathway, a canonical driver of fibrosis, induces epithelial-to-mesenchymal transition (EMT), enabling epithelial hepatocytes to acquire invasive, mesenchymal characteristics. Concurrently, activation of the NF-κB pathway supports a chronic inflammatory state that fosters genetic instability and cell survival. Wnt/β-catenin signaling, frequently amplified in HCC, promotes proliferation and stemness of liver cancer cells. The remodeling of the ECM not only provides structural support for tumor expansion but also modulates cellular signaling, mechanotransduction, and biochemical gradients that sculpt the tumor niche.

Mitochondrial dysfunction, emerging as a critical feature of the fibrotic liver, contributes to oxidative stress and metabolic reprogramming conducive to cancer initiation. Damaged mitochondria release reactive oxygen species (ROS) that cause DNA damage, while alterations in mitochondrial metabolism favor bioenergetic flexibility necessary for cancer cells under hypoxic conditions. Epigenetic modifications, including DNA methylation and histone alterations, further refine gene expression patterns that lock hepatocytes into malignant phenotypes. In parallel, shifts in the immune microenvironment, such as expansion of tumor-associated macrophages and regulatory T cells, perpetuate immune evasion and tumor tolerance.

Despite the complexity of these intertwined mechanisms, co-author Dr. Peng Luo of Southern Medical University emphasizes that the fibrosis-to-cancer transition is not an inexorable fate. By targeting the activation state of HSCs or disrupting immune checkpoint pathways that enable immune evasion, therapeutic interventions can intercept the cascade of events culminating in hepatocellular carcinoma. Such strategies herald a paradigm shift towards early interception rather than late-stage treatment of liver cancer.

Emerging diagnostic technologies hold promise for earlier detection and improved prognosis in patients at risk of HCC. Liquid biopsy approaches, analyzing circulating tumor DNA and exosomes, offer minimally invasive means to detect molecular signatures of tumorigenesis before clinically apparent lesions develop. These techniques could revolutionize surveillance in chronic liver disease, enabling timely intervention and personalized therapeutic strategies.

Therapeutically, novel agents that selectively target cancer-associated fibroblasts are gaining traction. Fibroblast activation protein (FAP) inhibitors and chimeric antigen receptor T (CAR-T) cells designed to recognize and eliminate CAFs disrupt the supportive tumor stroma, attenuating tumor growth and invasiveness. By dismantling the pro-tumor microenvironment, these modalities complement direct tumor-targeting treatments and may overcome resistance mechanisms entrenched in the fibrotic niche.

Combination therapies that simultaneously abrogate fibrogenic drivers and amplify anti-tumor immunity emerge as particularly potent strategies. Immune checkpoint inhibitors, which have revolutionized oncology, show enhanced efficacy when paired with agents that reduce fibrosis and ECM stiffening, thereby allowing immune effector cells to infiltrate tumors more effectively. Modulating the fibrotic microenvironment thus represents a critical adjunct to immunotherapy in HCC.

The urgency of these findings is underscored by the grim clinical reality: while liver fibrosis remains reversible to some extent, once hepatocellular carcinoma develops, patient survival rates plummet dramatically. Understanding the molecular checkpoints governing fibrosis progression and malignant transformation therefore offers actionable targets for preventive therapeutics and better clinical outcomes.

Future research directions must focus on intricate cell-to-cell communications within the hepatic microenvironment, integrating single-cell transcriptomics, proteomics, and spatial biology to unravel fibroblast heterogeneity and immune cell dynamics. Such multi-omics approaches promise to identify novel biomarkers and therapeutic targets, tailoring interventions to the nuanced landscape of individual patients.

In the battle against hepatocellular carcinoma, this expanding knowledge of the fibrosis-cancer axis positions the scientific and medical community on the cusp of transformative breakthroughs. By intercepting disease progression at the nexus of chronic fibrosis and oncogenesis, it may soon be possible to dramatically reduce the global burden of this lethal cancer, offering renewed hope to millions worldwide.

Subject of Research: Not applicable
Article Title: Decoding the hepatic fibrosis-hepatocellular carcinoma axis: from mechanisms to therapeutic opportunities.
News Publication Date: 1-Jul-2025
Web References: http://dx.doi.org/10.1007/s12072-025-10838-y
References: Authors declare no competing interests
Keywords: Cancer, Liver